1. Adamczyk B. Najnowsze spojrzenie na immunopatologię stwardnienia rozsianego. https://www.mp.pl/sm/przeglad-badan/336002,najnowsze-spojrzenie-na-immunopatologie-stwardnienia-rozsianego (dostęp 27 listopada 2023).
2.
Adamczyk-Sowa M, Adamczyk B, Kułakowska A, Rejdak K, Nowacki P. Secondary progressive multiple sclerosis – from neuropathology to definition and effective treatment. Neurol Neurochir Pol 2020; 54 (5): 384-98.
3.
Bourgault C, Mcgregor M, Barkun J, Brodie W, Brophy J, Johnston J et al. REPORT NUMBER 3. Muhc.ca. Published 2002. (dostęp 27 listopada 2023) https://muhc.ca/sites/default/files/micro/m-TAU/Mitoxantrone.pdf.
4.
Brola W, Sobolewski P, Flaga S, Fudala M, Szczuchniak W, Stoiński J et al. Prevalence and incidence of multiple sclerosis in central Poland, 2010–2014. BMC Neurol. 2016; 16 (1): 134.
5.
Brown JWL, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A et al. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA 2019; 321 (2): 175.
6.
Butzkueven H, Kappos L, Wiendl H, Trojano M, Spelman T, Chang I et al. Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP). J Neurol Neurosurg Psychiatry 2020; 91 (6): 660-8.
7.
Coyle PK. What can we learn from sex differences in MS? J Pers Med. 2021; 11(10): 1006.
8.
Cross A, Riley C. Treatment of multiple sclerosis. Continuum (Minneap Minn). 2022; 28 (4): 1025-1051.
9.
Dayama A, Bhargava R, Kurmi S, Jain S, Dua V. Autologous stem cell transplant in adult multiple sclerosis patients: A study from North India. Neurol India 2020; 68 (2): 454.
10.
Dymecka J, Gerymski RJ. Niepełnosprawność a jakość życia pacjentów ze stwardnieniem rozsianym: mediacyjna rola zapotrzebowania na wsparcie społeczne. Człowiek Niepełnosprawność Społeczeństwo 2019; 46: 63-78.
11.
Edan G, Le Page E. Induction therapy for patients with multiple sclerosis: Why? When? How? CNS Drugs 2013; 27 (6): 403-9.
12.
Lefort M, Le Corre G, Le Page E, Rizzato C, Le Port D, Michel L et al. Ten-year follow-up after mitoxantrone induction for early highly active relapsing-remitting multiple sclerosis: An observational study of 100 consecutive patients. Rev Neurol (Paris) 2022; 178 (6): 569-79.
13.
Morrow SA, Clift F, Devonshire V, Lapointe E, Schneider R, Stefanelli M et al. Use of natalizumab in persons with multiple sclerosis: 2022 update. Mult Scler Relat Disord 2022; 65 (103995): 103995.
14.
Muraro PA, Pasquini M, Atkins HL, Bowen JD, Farge D, Fassas A et al. Long-term outcomes after autologous hematopoietic stem cell transplantation for multiple sclerosis. JAMA Neurol 2017; 74 (4): 459.
15.
Ruggieri S, Pontecorvo S, Tortorella C, Gasperini C. Induction treatment strategy in multiple sclerosis: a review of past experiences and future perspectives. Mult Scler Demyelinating Disord 2018; 3 (1).
16.
Rush CA, MacLean HJ, Freedman MS. Aggressive multiple sclerosis: proposed definition and treatment algorithm. Nat Rev Neurol 2015; 11 (7): 379-89.
17.
Scott LJ, Figgitt DP. Mitoxantrone: A Review of its Use in Multiple Sclerosis. CNS Drugs 2004; 18 (6): 379-96.
18.
Szwed M. Mitoksantron – antybiotyk antrachinonowy. Postepy Hig Med Dosw 2014; 68: 198-208.
19.
Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018; 17 (2): 162-73.
20.
Tur C, Carbonell-Mirabent P, Cobo-Calvo Á, Otero-Romero S, Arrambide G, Midaglia L et al. Association of early progression independent of relapse activity with long-term disability after a first demyelinating event in multiple sclerosis. JAMA Neurol. 2023; 80 (2): 151.
21.
Wnuk M, Maluchnik M, Perwieniec J, Podwojcic K, Szelag M, Walkiewicz D et al. Multiple sclerosis incidence and prevalence in Poland: Data from administrative health claims. Mult Scler Relat Disord 2021; 55 (103162): 103162.
